Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27747695 | 0.83 | CHRNB2 (0.34) | CHRNB2CHRNA4CHRNB4CHRNA3TSHR | |
| SCHEMBL487565 | 0.80 | ALDH1A1 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CYP11B1 | |
| SCHEMBL24610550 | 0.78 | CPB2 (0.31) | — | |
| SCHEMBL15164059 | 0.77 | CHRNB2 (0.39) | CHRNB2CHRNA4 | |
| SCHEMBL3586153 | 0.74 | — | — | |
| SCHEMBL2716190 | 0.74 | CYP11B1 (0.51) | CHRNB2CHRNA4CYP11B1CYP11B2 | |
| SCHEMBL28603454 | 0.72 | — | — | |
| SCHEMBL16879533 | 0.72 | ALDH1A1 (0.41) | — | |
| SCHEMBL3396077 | 0.72 | LMNA (0.38) | TSHRMAPK1KMT2A | |
| SCHEMBL30023642 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115836054-B | IL4I1 inhibitors and methods of use | 默沙东有限责任公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-115836054-A | IL4I1 inhibitors and methods of use | 默沙东有限责任公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-2004606-B1 | SUBSTITUTED ENAMINOCARBONYL COMPOUNDS | BAYER CROPSCIENCE AG (DE) | 2013-04-24 | — | — | EP | disclosed |
| US-8106212-B2 | Substituted enaminocarbonyl compounds | BAYER CROPSCIENCE AG (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20090247551-A1 | SUBSTITUTED ENAMINOCARBONYL COMPOUNDS | BAYER CROPSCIENCE AG (DE) | 2009-10-01 | — | — | US | disclosed |
| EP-2004606-A1 | SUBSTITUTED ENAMINOCARBONYL COMPOUNDS | Bayer CropScience AG (DE) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007115643-A1 | SUBSTITUTED ENAMINOCARBONYL COMPOUNDS | BAYER CROPSCIENCE AG (DE) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247551-A1 | SUBSTITUTED ENAMINOCARBONYL COMPOUNDS | DDT, NPEPPS, L3MBTL4 | CHRNB2 3544/4885CHRNA4 3307/4885CHRNB4 3124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.